Migraines and Seizures
NexGen's discovery of the common pathogenesis underlying seizures and migraines finally provides a coherent explanation for all of the observations and symptoms, a new understanding of the risk factors to be avoided, and most importantly allows for a novel pathogenesis based treatment approach in contrast to the symptom based treatment approaches used today. Existing drugs can be repurposed to rapidly provide relief to the 50 million seizure patients and 300 million migraine sufferers worldwide.
March 1, 2012 Press Release (PDF)
• Executive Summary (HTML)
(PDF)
• Pending Patent Application (PDF)
Targeted Transient Ribosomal Inhibition (TTRI)
TTRI silences expression of every protein involved in the underlying etiology and pathology of a disease condition in a target tissue mass, without adverse effect on normal cells. The therapeutic effect is targeted Antiproliferative, Anti-Inflammatory, and Antiviral activity. NexGen believes TTRI will set un unbeatable potency standard against single protein target technologies (Antibody or RNAi) in indications that involve a broad spectrum of protein synthesis such as inflammation mediated hyperproliferation (psoriasis, COPD, RA) or viral infections with accompanying inflammation (herpes lesions, influenza including any strain of H5N1).
• Executive Summary (HTML)
(PDF)
• Slide Show (PDF)
• Full Product, Clinical, and Patent Data (PDF)
• Comparison of TTRI to RNAi (HTML)
Cancer
Today’s chemotherapy protocols fail to cure the vast majority of cancers. NexGen Biomedical, Inc. has identified the major reasons for this failure and has pursued a solution termed Tumor Specific (TS) Cell Cycle Synchronous Chemotherapy (CCSC). The novel protocols are protected by a series of issued and pending patents. Detailed disclosures are provided in US Patent 7,507,704 (PDF) and in a detailed slide show on Cancer and Chemotherapy.
Summary and Overview Documents are provided below:
• Executive Summary (HTML)
(PDF)
• TS - CCSC Full Science and Business Slides (PDF)
NexGen Biomedical, Inc., San Jose, CA Contact Info: Mark Zamoyski, e-mail to:mark@nexgen.biz
DISCLAIMER AND IMPORTANT NOTICE:The Compositions and Methods presented on this website are all in preclinical stages. They are based only on our understanding of the proposed underlying mechanisms of action and on any available coincidental corroborative empirical evidence, any of which may in fact turn out not to be correct, or may be prevented from functioning as envisioned because of other factors or mechanisms of action not contemplated or considered, or may even cause harm because of factors or mechanisms of action not anticipated. The process of obtaining FDA approvals has not been started in any of the areas disclosed on this website. The disclosures here are purely for scientific information exchange purposes, representing one scientific point of view, and are not intended to suggest, or be used for, any proposed medical treatments. NexGen Biomedical, Inc. is a California corporation established in 1999.
© 2002 - 2012 Mark Zamoyski & NexGen Biomedical, Inc.